Global Infectious Diseases Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Apr-2017
No. of pages: 800
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Global Infectious Diseases Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the infectives partnering deals and agreements entered into by the worlds leading healthcare companies

Global Infectious Diseases Partnering 2010 to 2017 provides the full collection of Infectious Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Infectious Diseases partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Infectious Diseases partnering agreement structure

Infectious Diseases partnering contract documents

Top Infectious Diseases deals by value

Most active Infectious Diseases dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.

The report presents financial deal terms values for Infectious Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Infectious Diseases dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Infectious Diseases dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Infectious Diseases deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Infectious Diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Infectious Diseases deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Infectious Diseases partnering deals by specific Infectious Diseases target announced since 2010. The chapter is organized by specific Infectious Diseases therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Infectious Diseases partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Diseases partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Diseases technologies and products.

Report scope

Global Infectious Diseases Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Infectious Diseases trends and structure of deals entered into by leading companies worldwide.

Global Infectious Diseases Partnering 2010 to 2017 includes:

Trends in Infectious Diseases dealmaking in the biopharma industry since 2010

Analysis of Infectious Diseases deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Infectious Diseases deal contract documents

Comprehensive access to over 3500 Infectious Diseases deal records

The leading Infectious Diseases deals by value since 2010

Most active Infectious Diseases dealmakers since 2010

The report includes deals for the following indications:

Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile, Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other bacterial indications

Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1 (Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio, Respiratory syncytial virus (RSV), Zika, plus other viral indications.

Parasitic

Fungal: Nail Psoriasis, Onychomycosis (Nail infection), plus other fungal indications

Tropical: African trypanosomiasis (Sleeping sickness), Dengue fever, Malaria, West Nile Virus, Yellow fever, plus other tropical indications

In Global Infectious Diseases Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Infectious Diseases Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 1,500 infectious diseases deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Infectious Diseases Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Infectious Diseases deal trends since 2010

Access Infectious Diseases deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Infectious Diseases partner companies

Comprehensive access to over 750 links to actual Infectious Diseases deals entered into by the world's biopharma companies

Indepth review of Infectious Diseases deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Infectious Diseases opportunities

Uncover companies actively partnering Infectious Diseases opportunities

Global Infectious Diseases Partnering 2010-2017: Deal trends, players and financials

Table of Contents
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Diseases dealmaking
2.1. Introduction
2.2. Infectious Diseases partnering over the years
2.3. Infectious Diseases partnering by deal type
2.4. Infectious Diseases partnering by industry sector
2.5. Infectious Diseases partnering by stage of development
2.6. Infectious Diseases partnering by technology type
2.7. Infectious Diseases partnering by therapeutic indication

Chapter 3 -Financial deal terms for Infectious Diseases partnering
3.1. Introduction
3.2. Disclosed financials terms for Infectious Diseases partnering
3.3. Infectious Diseases partnering headline values
3.4. Infectious Diseases deal upfront payments
3.5. Infectious Diseases deal milestone payments
3.6. Infectious Diseases royalty rates

Chapter 4 - Leading Infectious Diseases deals and dealmakers
4.1. Introduction
4.2. Most active in Infectious Diseases partnering
4.3. List of most active dealmakers in Infectious Diseases
4.4. Top Infectious Diseases deals by value

Chapter 5 - Infectious Diseases contract document directory
5.1. Introduction
5.2. Infectious Diseases partnering deals where contract document available

Chapter 6 - Infectious Diseases dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Infectious Diseases therapeutic target

Appendices

Appendix 1 - Directory of Infectious Diseases deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Infectious Diseases deals by deal type 2010 to 2017
Appendix 3 - Directory of Infectious Diseases deals by stage of development 2010 to 2017
Appendix 4 - Directory of Infectious Diseases deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Table of figures
Figure 1: Infectious Diseases partnering since 2010
Figure 2: Infectious Diseases partnering by deal type since 2010
Figure 3: Infectious Diseases partnering by industry sector since 2010
Figure 4: Infectious Diseases partnering by stage of development since 2010
Figure 5: Infectious Diseases partnering by technology type since 2010
Figure 6: Infectious Diseases partnering by indication since 2010
Figure 7: Infectious Diseases deals with a headline value
Figure 8: Infectious Diseases deals with upfront payment values
Figure 9: Infectious Diseases deals with milestone payment
Figure 10: Infectious Diseases deals with royalty rates
Figure 11: Active Infectious Diseases dealmaking activity- 2010 to 2017
Figure 12: Top Infectious Diseases deals by value since 2010
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting&hellip
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and&hellip
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries,&hellip
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the&hellip
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The&hellip
  • Global Cephalosporin Drugs Sales Market Report 2017
    Published: 25-Jul-2017        Price: US 4000 Onwards        Pages: 111
    In this report, the global Cephalosporin Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Cephalosporin Drugs for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan......
  • Global Cephalosporin Drugs Market Research Report 2017
    Published: 20-Jul-2017        Price: US 2900 Onwards        Pages: 110
    In this report, the global Cephalosporin Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Cephalosporin Drugs in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China......
  • Global and Europe Antibiotics Market - Analysis and Outlook to 2022
    Published: 19-Jul-2017        Price: US 2960 Onwards        Pages: 127
    This report presents a comprehensive overview of the Antibiotics market in Europe. This shares the history data information from 2012 to 2016, and forecast from 2017 to 2022. This report provides a detailed analysis of the market, its dynamics, structure, characteristics, main players, growth and demand drivers, etc. As a Detailed Analysis report, it covers all details inside analysis and opinion in Antibiotics industry. This report focus Global and Europe market, i......
  • Sepsis - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 297
    Sepsis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sepsis - Pipeline Review, H2 2017, provides an overview of the Sepsis (Infectious Disease) pipeline landscape. Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This re......
  • Lyme Disease - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 33
    Lyme Disease - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lyme Disease - Pipeline Review, H2 2017, provides an overview of the Lyme Disease (Infectious Disease) pipeline landscape. Lyme disease is a bacterial infection transmitted by a tick. Lyme disease is caused by the bacterium Borrelia burgdorferi. Symptoms include rash, fever, chills, fatigue, body aches and headache. Risk fa......
  • Typhoid Fever - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 47
    Typhoid Fever - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Typhoid Fever - Pipeline Review, H2 2017, provides an overview of the Typhoid Fever (Infectious Disease) pipeline landscape. Typhoid fever is an infection that causes diarrhea and a rash. It is most commonly due to a type of bacterium called Salmonella typhi (S. typhi). Symptoms include abdominal tenderness, agitation, chi......
  • Cholera - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 43
    Cholera - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cholera - Pipeline Review, H2 2017, provides an overview of the Cholera (Infectious Disease) pipeline landscape. Cholera is an acute infectious disease caused by a bacterium, Vibrio cholera, which results in a painless, watery diarrhea in humans. Symptoms of cholera can begin as soon as a few hours or as long as five days after ......
  • Anthrax - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 142
    Anthrax - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H2 2017, provides an overview of the Anthrax (Infectious Disease) pipeline landscape. Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the ......
  • Streptococcus pyogenes Infections - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 37
    Streptococcus pyogenes Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Streptococcus pyogenes Infections - Pipeline Review, H2 2017, provides an overview of the Streptococcus pyogenes Infections (Infectious Disease) pipeline landscape. Streptococcus pyogenes infections are caused by Streptococcus pyogenes, a spherical, Gram-positive bacterium. Symptoms include significant ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs